RG
RARE icon

Redmile Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Redmile Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-67,425
Closed -$6.9M – 66
2015
Q2 		$6.9M Sell
67,425
-265,175
-80% -$20.6M 0.57% 44
2015
Q1 		$20.7M Buy
+332,600
New +$18.5M 1.85% 18

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Redmile Group's RARE Position: Q3 2015 in Review

Redmile Group sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2015, closing a stake of 67,425 shares — an estimated $6.9M sold.

Redmile Group first reported a position in RARE in Q1 2015 and held it in 2 quarters. The position peaked at $20.7M in Q1 2015. 161 funds tracked by Wall St. Rank hold RARE as of Q3 2015.

  • Redmile Group reported no remaining Ultragenyx Pharmaceutical position as of Q3 2015 after selling out during the quarter.
  • Redmile Group sold 67,425 Ultragenyx Pharmaceutical shares in Q3 2015, an estimated $6.9M.
  • Redmile Group first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 2 quarters.
  • Redmile Group's Ultragenyx Pharmaceutical position peaked at $20.7M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2015.

Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.